65th ASH Annual Meeting & Exposition: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Oral and Poster Abstracts
Oral

Research, Translational Research, immune mechanism, immunology, Biological Processes, molecular biology, multi-systemic interactions, pathogenesis

Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)

Moderators:

Jens Hillengass, MD, PhD, Roswell Park Comprehensive Cancer Center and Giada Bianchi, MD, Dana-Farber Cancer Institute

Disclosures:

Hillengass: GSK: Consultancy, Research Funding; Skyline: Consultancy; Oncopeptides: Consultancy; Sanofi: Consultancy; Axxess Network: Consultancy; OncLive: Consultancy; Janssen: Consultancy, Other: DSMB; Prothena: Consultancy; Amgen: Other: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events; Beigene: Other: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events; ESMO Florida: Other: Other: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events; Targeted Oncology: Other: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events; Angitia: Consultancy; Sebia: Consultancy. Bianchi: Prothena: Consultancy.

These abstracts examine the relationship between MM cells and the TME in treatment response.

4:00 PM

331

Characterization of Multiple Myeloma Subpopulations Associated with Treatment Resistance By Single-Cell RNA Sequencing

Takahiro Kamiya, MD^1,2^*, Motohiko Oshima, PhD¹^*, Shuhei Koide, PhD¹^*, Yaeko Nakajima-Takagi, PhD¹^*, Kazumasa Aoyama, PhD¹^*, Satoshi Kaito, MD, PhD¹^*, Naoki Itokawa, MD, PhD¹^*, Masayuki Yamashita, MD, PhD¹, Noriko Doki, MD, PhD³, Keisuke Kataoka, MD, PhD^2,4 and Atsushi Iwama, MD, PhD¹

¹Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
²Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
³Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
⁴Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan

4:15 PM

332

Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development

Hussein Ghamlouch, PhD^1,2^*, Dylan Gagler, B.S.¹^*, Patrick Blaney, MS¹^*, Eileen Boyle, MBChB, PhD^1,3, Yubao Wang, PhD⁴^*, Liming Hou, PhD⁴^*, Ola Landgren, MD⁵, Francesco Maura, MD⁶, Aristotelis Tsirigos, PhD⁷, Gareth J. Morgan, M.D., Ph.D.⁴^* and Faith E. Davies, MD⁸

¹Perlmutter Cancer Center, NYU Langone Health, New York
²Inserm, Villejuif, FRA
³Department of Hematology, UCL Cancer Institute, London, United Kingdom
⁴Perlmutter Cancer Center, Multiple Myeloma Research Program, NYU Grossman School of Medicine, NYU Langone Health, New York, NY
⁵Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL
⁶Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, PALMETTO BAY, FL
⁷Applied Bioinformatics Laboratories, New York University School of Medicine, New York
⁸NYU Langone Health, New York, NY

4:30 PM

333

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Ross Firestone, MD, PhD¹, Devin McAvoy, BS²^*, Tala Shekarkhand, MS³^*, Edith Serrano⁴^*, Issam S. Hamadeh, Pharm.D.⁵^*, Alice Wang, Pharm.D.⁵^*, Menglei Zhu⁴^*, Dhwani Patel, MD³^*, Carlyn Tan, MD⁶, Malin Hultcrantz, MD, PhD³, Sham Mailankody, MBBS³, Hani Hassoun, MD³, Urvi A Shah, MD³, Neha Korde, MD³, Kylee H Maclachlan, MBChB, PhD³, Heather Landau, MD⁷, Michael Scordo⁸, Gunjan L. Shah, MD⁹^*, Oscar Boutros Lahoud⁷, Sergio A. Giralt, MD, FACP⁹, Kinga K Hosszu, PhD²^*, David Chung, MD, PhD⁹, Alexander Lesokhin, MD³ and Saad Z Usmani, MD⁹

¹Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY
³Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Myeloma Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

4:45 PM

334

High-Throughput Plasma Proteomics to Define the Precursor Multiple Myeloma Proteome and Identify Candidate High-Risk Disease Biomarkers of Progression

Elizabeth D. Lightbody, PhD^1,2,3, D. R. Mani, PhD¹^*, Hasmik Keshishian, PhD¹^*, Habib El-Khoury, MD²^*, Ankit K. Dutta, PhD²^*, Hadley Barr, BSc²^*, Namrata Udeshi, PhD¹^*, Luca Bertamini, MD²^*, Nang Kham Su, MSc²^*, Cody J. Boehner, BSc²^*, Laura Hevenor, BS²^*, Katherine Towle, BS²^*, Grace Fleming, BSc²^*, Christian Cea-Curry, MSc²^*, Jacqueline Perry, MPH²^*, Erica M. Horowitz, BA²^*, Maya Davis, BA²^*, Annie Cowan, BA²^*, Catherine R. Marinac, PhD², Michael Gillette, MD, PhD¹^*, Steven A. Carr, PhD¹^* and Irene M. Ghobrial, MD^1,2,3

¹Broad Institute of MIT and Harvard, Cambridge, MA
²Dana-Farber Cancer Institute, Boston, MA
³Harvard Medical School, Boston, MA

5:00 PM

335

Mezigdomide Reverses T-Cell Exhaustion through Degradation of Aiolos/Ikaros and Reinvigoration of Cytokine Production Pathways

Hsiling Chiu, MA¹^*, Junfei Zhao, Ph.D¹^*, Maria Ortiz Estevez, Ph. D²^*, Patrick R Hagner, PhD¹^* and Anita K. Gandhi, PhD³

¹Bristol Myers Squibb, Summit, NJ
²Bristol Myers Squibb, Sevilla, Spain
³Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ

5:15 PM

336

Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells

Xiaoli Mi, MD¹, Alex Penson, PhD¹^*, Omar Abdel-Wahab, MD¹ and Sham Mailankody, MBBS^2,3

¹Memorial Sloan Kettering Cancer Center, New York, NY
²Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
³Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651.O1.6 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment